Checkpoint Therapeutics Stock
Checkpoint Therapeutics Stock
Checkpoint Therapeutics is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
With a target price of 30 € there is potential for a 5885.63% increase which would mean more than doubling the current price of 0.5 € for Checkpoint Therapeutics.
Pros and Cons of Checkpoint Therapeutics in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Checkpoint Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics | - | - | - | - | - | - | - |
| Ardelyx Inc. | 1.100% | 40.927% | 22.899% | 104.125% | 47.266% | 54.764% | - |
| Evolus Inc | -0.810% | 14.019% | 1.667% | 60.526% | 34.807% | 75.540% | - |
| Salarius Pharmaceuticals Inc. | -6.170% | 0.472% | -0.930% | -70.417% | -23.243% | -98.346% | -99.993% |
Comments
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its price target lowered by analysts at B. Riley from $8.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat